PLAU and apparent mineralocorticoid excess: Urokinase or urokinase (UK)-type plasminogen activator (uPA), a serine protease that functions by resolving clots via catalyzing the conversion of plasminogen to plasmin, is the most widely used drug for treating APE (Sasahara et al., 1967; Cheng et al., 2002).